Home > Healthcare > Pharmaceuticals > Finished Drug Form > Oncology Precision Medicine Market

Oncology Precision Medicine Market Share

Report ID: GMI11876
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Oncology Precision Medicine Market Share

The market is characterized by the presence of several key players and a focus on substantial investments and innovations. These companies invest significantly in research and development to introduce advanced precision therapeutics. Market competition is intensified by stringent regulatory requirements and the need for continuous product enhancements to meet evolving clinical needs. Strategic initiatives such as mergers, acquisitions, and collaborations are common strategies employed by key players to strengthen their market position and expand their geographic footprint.

Oncology Precision Medicine Market Companies

Prominent players operating in the oncology precision medicine industry include:

AbbVie
AstraZeneca
Bayer
Blueprint Medicines Corporation
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche
GlaxoSmithKline
Merck
Novartis
Organon
Pfizer

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global oncology precision medicine industry was valued at USD 41.7 billion in 2023 and is expected to grow at a 9.1% CAGR from 2024 to 2032, driven by increasing cancer incidences and advancements in genomic sequencing.

The breast cancer segment generated USD 12.8 billion in revenue in 2023, benefiting from the development of targeted therapies and personalized treatment approaches.

The North America oncology precision medicine market recorded USD 19.3 billion in 2023 and is anticipated to grow at a 9.4% CAGR from 2024 to 2032, supported by a robust healthcare infrastructure in the U.S. and Canada.

Key players in the industry include AbbVie, AstraZeneca, Bayer, Blueprint Medicines Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche, and GlaxoSmithKline.